Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CTTH | 8-K | neutral | 3/10 | CTT Pharmaceutical Holdings filed an 8-K with Item 4.01 (Change in Accountant), attaching a letter from predecessor audi | Oct 9, 2026 |
| CRVO | 8-K | neutral | 2/10 | CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation is available on its website. The fi | Oct 9, 2026 |
| LNAI | 8-K | bearish | 6/10 | Lunai Bioworks submitted a formal request to Nasdaq on October 9, 2026, asking for an immediate trading suspension in it | Oct 9, 2026 |
| EXOZ | 8-K | neutral | 2/10 | EXOZYMES INC. filed an 8-K attaching an investor presentation dated October 6, 2026, that may be provided to investment | Oct 9, 2026 |
| JAZZ | 8-K | neutral | 2/10 | Jazz Pharmaceuticals disclosed that EVP and Chief Commercial Officer Samantha Pearce plans to retire, effective upon app | Oct 9, 2026 |
| ATOS | 8-K | neutral | 4/10 | Atossa Therapeutics entered into a Contingent Value Rights (CVR) Agreement, declaring a dividend of one CVR per share of | Oct 9, 2026 |
| QNCX | 8-K | bullish | 7/10 | Quince Therapeutics has completed its transformation into IRulya Therapeutics, executing a full leadership overhaul with | Oct 9, 2026 |
| RNA | 8-K/A | neutral | 2/10 | Atrium Therapeutics filed an 8-K/A to correct the share count disclosed in its October 8, 2026 original 8-K regarding a | Oct 9, 2026 |
| XFOR | 8-K | mixed | 6/10 | X4 Pharmaceuticals entered into a $150M senior secured term loan facility with K2 HealthVentures, receiving an $80M firs | Oct 8, 2026 |
| FBLG | 8-K | bearish | 6/10 | FibroBiologics issued a $1.2M convertible debenture to Peak One Opportunity Fund at a 15% original issue discount, recei | Oct 8, 2026 |
| ZTS | 8-K | neutral | 2/10 | Zoetis declared a Q4 2026 dividend of $0.53 per share, payable December 1, 2026 to holders of record as of October 30, 2 | Oct 8, 2026 |
| TENX | 8-K | neutral | 5/10 | Tenax Therapeutics filed an 8-K announcing a temporary pause in enrollment of its Phase 3 LEVEL-2 trial of TNX-103 (oral | Oct 8, 2026 |
| AARD | 8-K | neutral | 2/10 | Aardvark Therapeutics appointed David (Zhongwei) Zhang, Ph.D., MBA, as a Class II independent director, effective Octobe | Oct 8, 2026 |
| VREOF | 8-K | bullish | 6/10 | Vireo Growth Inc. (VREOF) subsidiaries closed a $60M term loan with Needham Bank on October 2, 2026, using proceeds to r | Oct 8, 2026 |
| PCRX | 8-K | bullish | 7/10 | Pacira BioSciences has entered into a definitive agreement to be acquired by Viatris for $36.50 per share in cash, repre | Oct 8, 2026 |
| VIR | 8-K | neutral | 4/10 | Vir Biotechnology announced that the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN dual-maske | Oct 8, 2026 |
| VTRS | 8-K | bullish | 7/10 | Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $36.50 per share in cash, representing an aggregate e | Oct 8, 2026 |
| BIAF | 8-K | bullish | 4/10 | bioAffinity Technologies announced that the Japan Patent Office issued a Notice of Allowance for a patent covering its C | Oct 8, 2026 |
| EDIT | 8-K | bullish | 6/10 | Editas Medicine announced regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial of EDIT-401, | Oct 8, 2026 |
| RNA | 8-K | bearish | 6/10 | Atrium Therapeutics announced a ~$50M private placement, selling 5,170,384 common shares at $7.93/share and pre-funded w | Oct 8, 2026 |
| CATX | 8-K | bullish | 6/10 | Perspective Therapeutics announced FDA Fast Track Designation for PSV359, its FAP-targeted alpha-particle therapy for so | Oct 8, 2026 |
| CTTH | 8-K | bearish | 6/10 | CTT Pharmaceutical Holdings' independent auditor, Holt & Patterson, LLC, resigned effective October 2, 2026, citing a de | Oct 7, 2026 |
| SCNX | 8-K | neutral | 4/10 | Scienture Holdings filed an 8-K confirming a 1-for-25 reverse stock split effective October 5, 2026, aimed at regaining | Oct 7, 2026 |
| MDCX | 8-K | neutral | 4/10 | Medicus Pharma Ltd. announced a 50-to-1 reverse share split effective October 12, 2026, to boost the bid price and regai | Oct 7, 2026 |
| GRDX | 8-K | neutral | 3/10 | GridAI Technologies Corp. made a third loan of $536,000 to Pronghorn Resources, LLC, bringing the total aggregate princi | Oct 7, 2026 |
| PHGE | 8-K | neutral | 4/10 | Tessera Defense & Homeland Security formalized employment agreements with CEO Michael Oster and CFO David Rokach on Octo | Oct 7, 2026 |
| CVKD | 8-K | bullish | 6/10 | Cadrenal Therapeutics announced a formal strategic process to maximize shareholder value, engaging Tungsten Advisors as | Oct 7, 2026 |
| PLSE | 8-K | bullish | 6/10 | Pulse Biosciences announced it has achieved its enrollment target of 164 evaluable patients in the NANOPULSE-AF IDE pivo | Oct 7, 2026 |
| RARE | 8-K | bullish | 6/10 | Ultragenyx entered into an asset purchase agreement on October 6, 2026 to sell a Rare Pediatric Disease Priority Review | Oct 7, 2026 |
| BCDA | 8-K | neutral | 3/10 | BioCardia filed an 8-K announcing a poster presentation of the CardiAMP HF II trial design at the HFSA Annual Scientific | Oct 7, 2026 |